S&P 5007,765.36▼0.5% Nasdaq27,193.34▼1.2% Dow51,231.64▲0.1% Russell 2K2,794.13▲0.0% 10-Yr5.23%−5bp VIX15.41+0.33 WTI$91.10▲3.2% Gold$4,157.80▲0.4% EUR/USD1.122▼0.3% BTC$83,126▲1.7% Nikkei70,036▼0.9%
At close · Thu, Oct 8, 2026
Daily Market Updates.

Earnings

Home›Earnings›Analyst Ratings›J&J faces MedTech issues after pharmaceutical division…

J&J faces MedTech issues after pharmaceutical division performance

Reported · Written up by our desk · Analyst Ratings

CNBC Earnings frames the latest quarter as a mixed outcome for Johnson & Johnson, noting that while the pharmaceutical business is performing, MedTech problems are weighing on results.

The outlet suggests the MedTech issues should be temporary, implying investors looking ahead may focus more on the ongoing strength in the pharmaceutical segment.

← Newer storyRising rates are clouding sentiment for big banks on Wall Street

More like this

EarningsGoldman Sachs upgraded after strong quarter signals solid execution
EarningsT-Mobile shares fall to 52-week low after SpaceX spectrum deal news
EarningsFTC-USDA inquiry into agricultural equipment competition pressures shares
EarningsInsiders bought shares in H.B. Fuller, signaling possible bottom
EarningsRetail stocks outperform peers with upcoming holiday earnings beats

Sources

CNBC EarningsJ&J's 6% slide on an imperfect quarter is a gift to prospective buyers

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.